Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
US biotech firm Array BioPharma has launched a new subsidiary to develop drugs using its ARRY-797 drug program, according to a filing with the US Securities and Exchange Commission (SEC). 30 December 2017
Robert Stewart is to leave his role as chief operating officer of Ireland-incorporated drugmaker Allergan to take the top job at Amneal Pharmaceuticals. 18 December 2017
In a candid admission, privately-owned German pharma major Boehringer Ingelheim has said that conflicting views over strategy are behind the departure of one of its most senior executives. 18 December 2017
In today’s world, cheap insults from people in high places – whether justified and evidence-backed or not – can do harm to the reputation and market value of pharma firms that can be difficult to repair. 15 December 2017
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017
Mundipharma network of independent associated companies has appointed Alberto Martinez as president and chief executive of Mundipharma International, with immediate effect. 13 December 2017
French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
Alligator Bioscience today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery. 4 December 2017
Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Germany’s Bayer announced today it will further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership. 1 December 2017
The Supervisory Board of Selvita has appointed Edyta Jaworska to the position of a management board member, responsible for the development of its integrated drug discovery services. 30 November 2017
Denmark-based allergy specialist ALK-Abelló today announced that Helle Skov, executive vice president of product supply and a member of ALK's board of management, leaves the company by mutual agreement. 29 November 2017
Following reports in Israeli press last week that struggling generics giant Teva Pharmaceutical Industries is gearing up to slash its global workforce, the company announced today a radical shakeup of its executive team which included, as expected, the ousting of R&D chief Michael Hayden. 27 November 2017
Canadian clinical-stage immuno-oncology (I-O) company Turnstone Biologics has named Mike Burgess as president of research and development (R&D). 16 November 2017
US pharma giant Pfizer has promoted Albert Bourla to the newly-created position of chief operating officer, effective January 1, 2018. 15 November 2017
UK-based Pertinax Pharma says that Nigel Brooksby, a former chairman of Sanofi UK, has been appointed as chairman of the company, where he will drive the commercialization of the company’s Pertinax. 14 November 2017